XM does not provide services to residents of the United States of America.
A
A

Amgen

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Consumer groups ask FTC to block Novo Holdings-Catalent deal

UPDATE 3-Consumer groups ask FTC to block Novo Holdings-Catalent deal Consumer groups and unions express competition concerns to FTC Deal could limit options for competitors developing GLP-1 drugs Concerns also raised about impact on gene therapy manufacturing Updates Oct. 17 story with Novo Holdings declining comment, paragraph 7 By Jody Godoy and Maggie Fick NEW YORK, Oct 18 (Reuters) - U.S.
A
A
N
N
P
R

Consumer groups ask FTC to block Novo Holdings-Catalent deal

Consumer groups ask FTC to block Novo Holdings-Catalent deal Consumer groups and unions express competition concerns to FTC Deal could limit options for competitors developing GLP-1 drugs Concerns also raised about impact on gene therapy manufacturing By Jody Godoy, Maggie Fick NEW YORK, Oct 17 (Reuters) - Five U.S. consumer groups and two large labor unions urged the U.S.
A
A
N
N
P
R

U.S. Constellation Energy, Morgan Stanley, Uber

U.S. RESEARCH ROUNDUP-Constellation Energy, Morgan Stanley, Uber Oct 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Constellation Energy, Morgan Stanley, and Uber, on Thursday. HIGHLIGHTS * Constellation Energy Corp CEG.O : J.P. Morgan initiates coverage with overweight rating * Illumina Inc ILMN.O : HSBC raises to buy from hold * Morgan Stanley MS.N : RBC raises target price to $122 from $108 * Uber UBER.N : Dai
A
A
A
B
B
C
C
C
G
I
S
V
U
U
G
U
W
A
A
C
C
D
D
F
F
P

U.S. STOCKS Bausch + Lomb, SpartanNash, Hologic

BUZZ-U.S. STOCKS ON THE MOVE-Bausch + Lomb, SpartanNash, Hologic Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street rose on Monday, with the S&P 500 and the Dow touching fresh intraday record highs, as investors geared up for a week packed with corporate earnings and crucial economic data that will likely test stretched stock market valuations.
A
A
H
N
N
T
W
K
L
S
T
U
W
U
U

Amgen falls as Truist downgrades to 'hold' on competition for experimental skin disease drug

BUZZ-Amgen falls as Truist downgrades to 'hold' on competition for experimental skin disease drug ** Shares of drugmaker Amgen AMGN.O fall 1% to $324.95 ** Truist Securities downgrades stock to "hold" from "buy", citing "extremely competitive" landscape for an experimental drug to treat atopic dermatitis or eczema ** Brokerage also raises PT to $33
A
R
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.